Patents by Inventor Akshaykant Chaturvedi
Akshaykant Chaturvedi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9765108Abstract: The present invention relates to polymorphic forms of 5-Azacytidine and the process for preparation thereof. The present invention further relates to Crystalline 5-azacytidine 5 designated as Form-SA-1 characterized by an X-ray powder diffraction pattern having at least four characteristic diffraction angle peaks at about 12.00, 12.60, 13.90, 15.15 and 31.40±0.20 2?°, which is useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of myelodysplastic syndrome.Type: GrantFiled: November 8, 2013Date of Patent: September 19, 2017Assignee: SHILPA MEDICARE LIMITEDInventors: Pradeep Shivakumar, Nagaraju Dasari, Ravi Kishore, Rizwan Ahmed, Akshaykant Chaturvedi
-
Patent number: 9732030Abstract: The present invention provides process for preparation of Fingolimod hydrochloride (I). Fingolimod hydrochloride (I) as Form-? obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.Type: GrantFiled: January 11, 2014Date of Patent: August 15, 2017Assignee: SHILPA MEDICARE LIMITEDInventors: Vimal Kumar Shrawat, Rafiuddin Dr, Akshaykant Chaturvedi
-
Patent number: 9708352Abstract: The present invention relates to a process for preparation of Echothiophate Iodide (I). Echothiophate Iodide (I) obtained by the process of the present invention is obtained as new crystalline form designated as Form-SET. The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.Type: GrantFiled: January 1, 2015Date of Patent: July 18, 2017Assignee: SHILPA MEDICARE LIMITEDInventors: Nagnnath Kokare, Venkatanarayana Bathula, Akshaykant Chaturvedi
-
Publication number: 20170107193Abstract: The present invention relates to process for the preparation of highly pure Lenalidomide (I). The invention also relates to crystalline Form-SL obtained by the process of the present invention., the said Form-SL being substantially pure and characterized by X-ray powder diffraction pattern comprising of at least seven peaks selected from 7.061, 12.860, 16.531, 18.698, 27.925, 33.212, 34.187, 35.253, 35.921 and 38.765±0.1°2?; a single un-split °2? peak at 7.813±-.1°2?; and a three-way split °2? peak at 20.467±0.1°2?. The invention further relates to pharmaceutical compositions comprising crystalline Form-SL of Lenalidomide, which may be useful for the treatment of cancer.Type: ApplicationFiled: August 1, 2014Publication date: April 20, 2017Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, LAVKUMAR UPALLA, PRASHANT PUROHIT, AKSHAYKANT CHATURVEDI
-
Publication number: 20170002031Abstract: The present invention relates to a process for preparation of Echothiophate Iodide (I). Echothiophate Iodide (I) obtained by the process of the present invention is obtained as new crystalline form designated as Form-SET. The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.Type: ApplicationFiled: January 1, 2015Publication date: January 5, 2017Applicant: SHILPA MEDICARE LIMITEDInventors: NAGNNATH KOKARE, VENKATANARAYANA BATHULA, AKSHAYKANT CHATURVEDI
-
Publication number: 20160264565Abstract: The present invention relates to a process for preparation of crystalline Form-SDI of Dasatinib (I). Said crystalline Form-SDI of Dasatinib is characterized by X-ray powder diffraction pattern comprising of at least seven 2?° peaks selected from the XRPD peak set of 5.8, 11.5, 12.7, 13.2, 17.3, 17.5, 18.1, 20.1, 20.5, 22.1, 25.4, 26.6, 26.8±0.20 2?°; IR spectrum having at least five absorption peaks selected from about 3390 cm?1, 2923 cm?1, 1621 cm?1, 1615 cm?1, 1537 cm?1, 1316 cm?1, 1061 cm?1, 815 cm?1 and 783 cm?1; and DSC isotherm comprising at least two endothermic peaks ranging between ?130° C. to 150° C., 160° C. to 175° C. or 280° C. to 290° C. The pharmaceutical compositions of the crystalline Form-SDI of Dasatinib or its hydrate thereof may be useful as an anti-cancer agent.Type: ApplicationFiled: April 24, 2014Publication date: September 15, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, PRADEEP POTHANA, SURESH GARBAPU, PRASHANT PUROHIT, AKSHAYKANT CHATURVEDI
-
Publication number: 20160214961Abstract: The present invention relates to novel pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate thereof. The present invention further relates to processes for preparation of the said substituted aryl acrylic acid addition salts of Crizotinib (I). The present application also provides pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate useful as active pharmaceutical ingredient in pharmaceutical composition comprising thereof, possessing anti-cancer activity.Type: ApplicationFiled: September 3, 2014Publication date: July 28, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: LAVKUMAR UPALLA, SRIRAM RAMPALLI, CHANTIBABU PATNEEDI, CHANDRASEKHAR DANGUDUBIYYAM, AKSHAYKANT CHATURVEDI
-
Publication number: 20160143850Abstract: The invention relates to a granulate composition comprising 90-99.95% w/w of Imatinib mesylate, 0.05-0.2% w/w of binder and 0-8% w/w of disintegrant, wherein the granulate composition is prepared using binder in isopropyl alcohol solvent. The invention also relates to pharmaceutical compositions comprising Imatinib mesylate, with high polymorphic stability and processes for preparation thereof. Said granulate composition comprising 90-99.95% w/w of Imatinib mesylate and their pharmaceutical compositions derived may be useful in the treatment of cancer.Type: ApplicationFiled: June 25, 2014Publication date: May 26, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: PRADEEP SHIVAKUMAR, KRISHNAMURTHY TOPPALADODDI, SANJAY UMACHIGI, BADRINATH ALAMPALLI, AKSHAYKANT CHATURVEDI
-
Patent number: 9278932Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.Type: GrantFiled: March 5, 2014Date of Patent: March 8, 2016Assignee: SHILPA MEDICARE LIMITEDInventors: Rafiuddin Dr, Vinod Kumar Singh, Nagnnath Kokare, Akshaykant Chaturvedi
-
Publication number: 20160060220Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.Type: ApplicationFiled: March 5, 2014Publication date: March 3, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: RAFIUDDIN DR, VINOD KUMAR SINGH, NAGNNATH KOKARE, AKSHAYKANT CHATURVEDI
-
Publication number: 20150344409Abstract: The present invention provides process for preparation of Fingolimod hydrochloride (I). Fingolimod hydrochloride (I) as Form-? obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.Type: ApplicationFiled: January 11, 2014Publication date: December 3, 2015Applicant: SHILPA MEDICARE LIMITEDInventors: VIMAL KUMAR SHRAWAT, RAFIUDDIN DR, AKSHAYKANT CHATURVEDI
-
Publication number: 20150284421Abstract: The present invention relates to lyophilized formulations comprising crystalline 5-azacytidine and process for preparing lyophilized formulations comprising crystalline 5-azacytidine.Type: ApplicationFiled: November 8, 2013Publication date: October 8, 2015Applicant: SHILPA MEDICARE LIMITEDInventors: Pradeep Shivakumar, Nagaraju Dasari, Ravi Kishore, Rizwan Ahmed, Akshaykant Chaturvedi
-
Publication number: 20140336246Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.Type: ApplicationFiled: December 26, 2012Publication date: November 13, 2014Applicant: SHILPA MEDICARE LIMITEDInventors: Vimal Kumar Shrawat, Prashant Purohit, Rafiuddin Dr, Vinod Kumar Singh, Akshaykant Chaturvedi